Ganciclovir Resistant/Refractory Cytomegalovirus Infection in SOT Recipients and HSCT Patients (NCT05234723)
Epidemiological Burden of and Risk Factors for Ganciclovir Resistant/Refractory Cytomegalovirus in Solid Organ Transplant and Hematopoietic Stem Cell Transplant Patients: Multicentre Cohort Study
🩺 Plain-English Summary (8th-Grade Level)
The ReCySOHT study is a multicenter, retrospective, observational case-control study on the risk factors for developing a ganciclovir-resistant/refractory (GCV-RR) cytomegalovirus infection in patients receiving solid organ transplant (SOT) or hematopoietic stem cell transplant (HSCT). Aims of the study are to investigate the incidence of and risk factors for GCV-RR CMV infection in SOT recipients and HSCT patients in order to design further studies aimed at preventing and improving the patient management of GCV-RR CMV infections.
Who can join: Review the eligibility criteria below.
Location: MD Anderson Cancer Center — Houston, Texas
Age range: 18 Years
📋 "Do I Qualify?" — 1-Minute Self Screener
Instant ChecklistFull eligibility criteria are available on the official NIH protocol. View the criteria ↗
📍 All Participating Trial Locations (23 Sites)
- MD Anderson Cancer Center — Houston, Texas
- Institut Jules Bordet — Brussels,
- University Hospitals Leuven — Leuven,
- Helsinki University Central Hospital — Helsinki, Helsinki
- Centre Hospitalier Universitaire de Limoges — Limoges, Limoges
- IRCCS Azienda Ospedaliero-Universitaria di Bologna — Bologna, Bologna
- Humanitas Research Hospital — Rozzano, Milano
- Istituto mediterraneo per i trapianti e terapie ad alta specializzazione (ISMETT) — Palermo, Palermo
- Ospedale San Martino — Genova,
- Policlinico di Milano — Milan,
- Azienda Ospedaliero-Universitaria di Modena — Modena,
- Azienda Ospedaliera dei Colli — Naples,
- Azienda Ospedale-Università Padova — Padova,
- AOU Città della salute e della scienza — Torino,
- ASST dei Sette Laghi — Varese,
- São João University Hospital — Porto,
- Hospital Clinic — Barcelona,
- Instituto Maimónides de Investigación Biomédica de Córdoba — Córdoba,
- Gregorio Marañón General University Hospital — Madrid,
- University Hospital 12 de Octubre — Madrid,
- Centre hospitalier universitaire vaudois (CHUV) — Lausanne, Lausanne
- University Hospital Zurich — Zurich,
- Manchester University NHS Foundation Trust — Manchester,
📞 Contact the Study Coordinator
Phone: +390512144350
Email: renato.pascale@aosp.bo.it
Coordinator details come directly from the registered NIH protocol. Confirm the study is still recruiting before traveling.
💰 Cost, Insurance & Patient Rights
- 100% Free Items: The investigational treatment and protocol-required procedures are supplied at zero cost by the sponsor.
- Routine Patient Care: Under federal law (ACA § 2709) and many state statutes, routine care costs are covered during participation.
- Voluntary Participation: You may withdraw at any time without affecting your standard medical care.
More studies in Cytomegalovirus Infections
- Antiviral Cellular Therapy for Enhancing T-cell Reconstitution Before or After Hematopoietic Stem Cell Transplantation — Phoenix, Arizona
- Valganciclovir Prophylaxis Versus Preemptive Therapy for Cytomegalovirus in Living Donor Kidney Transplant Recipients — Guadalajara, Jalisco
- Letermovir for Secondary Prophylaxis in Solid Organ Transplant Recipients — Boston, Massachusetts
- Open Label Trial of Oral Letermovir for CMV Prophylaxis in Thoracic Transplant Recipients — Philadelphia, Pennsylvania
- T Cell Therapy of Opportunistic Cytomegalovirus Infection — Cleveland, Ohio
Explore by condition: All Cytomegalovirus Infections clinical trials
💡 How to Participate
- Check the checklist above to see if you may qualify.
- Contact the study coordinator using the phone/email above.
- Ask about the visit schedule, what is covered at no cost, and any travel support.
- Confirm with your own doctor before making a decision.